MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Staging

Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.

European Radiology 2018 July 2 [Link] Gudmundsson E, Labby Z, Straus CM, Sensakovic WF, Li F, Rose B, Cunliffe A, Kindler HL, Armato SG Abstract OBJECTIVES: The aim of this pilot study was to investigate the utility of haemodynamic parameters derived from dynamic contrast-enhanced computed tomography (DCE-CT) scans in the assessment of tumour response to […]

Comments Off on Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.

Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.

Journal of the National Cancer Institute 2018 March 1 [Link] Gill RR, Yeap BY, Bueno R, Richards WG Abstract BACKGROUND: Analysis of the International Association for the Study of Lung Cancer (IASLC) Malignant Pleural Mesothelioma (MPM) database revealed that clinical (cTNM) staging minimally stratified survival and was discrepant with pathological (pTNM) staging. To improve prognostic […]

Comments Off on Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

The Lancet. Respiratory Medicine. 2018 May 14 [Link] CalabrĂ² L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M Abstract BACKGROUND: Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve […]

Comments Off on Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Journal of Thoracic Oncology May 9 2018 [Link] Armato SG, Nowak AK Abstract Malignant pleural mesothelioma poses unique difficulties in tumor measurement and response assessment; however, robust and reproducible assessment of response is critically important in the conduct, interpretation, and reporting of clinical trials. The current de-facto standard for the assessment of mesothelioma tumor response, […]

Comments Off on Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma

The American Journal of Surgical Pathology 2017 October [Epub ahead of print] [Link] Pillappa R, Maleszewski JJ, Sukov WR, Bedroske PP, Greipp PT, Boland JM, Yi ES, Peikert T, Aubry MC, Roden AC Abstract Distinguishing reactive mesothelial proliferation from malignant mesothelioma (MM) can be difficult, particularly on small biopsies. In this scenario, a diagnosis of […]

Comments Off on Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma

The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database

International Journal of Surgery 2017 October [Epub ahead of print] [Link] Wang S, Ma K, Wang Q, Sun F, Shi Y, Zhan C, Jiang W Abstract BACKGROUND: Several staging systems for MPM have been introduced. However, none of them provide perfect survival stratification among heterogeneous patients. The aim of this population-based cohort study was to […]

Comments Off on The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database

The value of delayed phase enhanced imaging in malignant pleural mesothelioma

Journal of Thoracic Disease 2017 August [Link] Patel AM, et.al. Abstract BACKGROUND: Cross-sectional imaging of malignant pleural mesothelioma (MPM) can underestimate the presence of local tumor invasion. Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed. Here we estimate the optimal timing of MPM enhancement on magnetic resonance […]

Comments Off on The value of delayed phase enhanced imaging in malignant pleural mesothelioma

Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.

Cancer Medicine 2017 September [Epub ahead of print] [Link] Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A Abstract The aim of this study was to evaluate the role of metabolic […]

Comments Off on Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.

Clinical staging of malignant pleural mesothelioma: current perspectives

Lung Cancer 2017 August [Link] Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli G Abstract Malignant pleural mesothelioma (MPM) is a disease with limited therapeutic options, the management of which is still controversial. Diagnosis is usually made by thoracoscopy, which allows multiple biopsies with histological […]

Comments Off on Clinical staging of malignant pleural mesothelioma: current perspectives

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

The Lancet.Oncology 2017 July 17 [Epub ahead of print] [Link] Maio M, Scherpereel A, CalabrĂ² L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL Abstract BACKGROUND: New therapeutic strategies for malignant mesothelioma are […]

Comments Off on Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial